Diquafosol tetrasodium

Base Information

• Chemical Name: Diquafosol tetrasodium
• CAS No.: 211427-08-6
• Deprecated CAS: 266356-23-4
• Molecular Formula: C18H22N4Na4O23P4
• Molecular Weight: 878.2344
• UNII: X8T9SBH9LL
• NCI Thesaurus Code: C65437
• Pharos Ligand ID: YF4RQS74LDH2
• ChEMBL ID: CHEMBL1767408
• Mol file: 211427-08-6.mol

Synonyms:diquafosol;INS 365;INS-365;INS365

Chemical Property of Diquafosol tetrasodium

Chemical Property:

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• PSA: 455.01000
• Density: g/cm³
• LogP: -2.43740
• Hydrogen Bond Donor Count: 6
• Hydrogen Bond Acceptor Count: 23
• Rotatable Bond Count: 14
• Exact Mass: 877.9216081
• Heavy Atom Count: 53
• Complexity: 1460

Purity/Quality:

99% ^*data from raw suppliers

Diquafosoltetrasodium >98% ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

Useful:

• Canonical SMILES: C1=CN(C(=O)NC1=O)C2C(C(C(O2)COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OCC3C(C(C(O3)N4C=CC(=O)NC4=O)O)O)O)O.[Na+].[Na+].[Na+].[Na+]
• Isomeric SMILES: C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=CC(=O)NC4=O)O)O)O)O.[Na+].[Na+].[Na+].[Na+]
• Description: Diquafosol (INS-365) was approved in Japan in 2010 as a 3% ophthalmic solution for treatment of dry eye disease. Clinical diagnosis of dry eye is difficult because the condition presents a variety of symptoms. Treatment options include tear supplements (lubricants), anti-inflammatory drugs (e.g., cyclosporine eye drops or steroid eye drops), and tear retention devices. Diquafosol is a unique agent for the treatment of dry eye in that it acts as a P2Y2 purinergic receptor agonist with the ability to activate this receptor on the ocular surface and stimulate water, lipid, and mucin secretion. Diquafosol is metabolized by phosphodiesterases to UTP, UDP, UMP, and uridine. Diquafosol has been well tolerated in clinical trials, with side effects being local to the ocular surface.In addition,no serious ocular or systemic adverse drug reactions were found during the clinical trials.
• Uses: Enhancement of mucosal hydration in the treatment of chronic dry eye (P2Y2 receptor antagonist).
• Clinical Use: Diquafosol tetrasodium was approved in April 2010 as Diquas ? ophthalmic solution 3% for the treatment of dry eye syndrome and launched in Japan by Santen Pharmaceuticals. Diquafosol tetrasodium was originally discovered by Inspire Pharmaceuticals. In 2001, it was licensed to Santen for co-development and commercialization in Asian countries, and co-developed in collaboration with Allergan for the countries outside of Asia. In the U.S., diquafosol tetrasodium was submitted for a New Drug Application (NDA) as Prolacria ?(2% ophthalmic formulation) in June 2003. However, it is still in Phase III clinical development for dry eye syndrome. Diquafosol tetrasodium, also known as INS- 365, is a P2Y2 receptor agonist, which activates P2Y2 receptor on the ocular surface, leading to rehydration through activation of the fluid pump mechanism of the accessory lacrimal glands on the conjunctival surface.